Report Detail
Covid-19 Impact on Global Drugs for Oncology Market Size, Status and Forecast 2020-2026
- RnM3973377 |
- 20 May, 2020 |
- Global |
- 132 Pages |
- QYResearch |
- Pharma & Healthcare
Drugs for Oncology market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Oncology market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Drugs for Oncology market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyzes the impact of Coronavirus COVID-19 on the Drugs for Oncology industry.
The key players covered in this study
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Market segment by Type, the product can be split into
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Market segment by Application, split into
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Drugs for Oncology status, future forecast, growth opportunity, key market and key players.
To present the Drugs for Oncology development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.
In this study, the years considered to estimate the market size of Drugs for Oncology are as follows:
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered: Ranking by Drugs for Oncology Revenue
- 1.4 Covid-19 Implications on Market by Type
- 1.4.1 Global Drugs for Oncology Market Size Growth Rate by Type: 2020 VS 2026
- 1.4.2 Chemotherapy
- 1.4.3 Targeted Therapy
- 1.4.4 Immunotherapy (Biologic Therapy)
- 1.4.5 Hormonal Therapy
- 1.4.6 Others
- 1.5 Market by Application
- 1.5.1 Global Drugs for Oncology Market Share by Application: 2020 VS 2026
- 1.5.2 Blood Cancer
- 1.5.3 Breast Cancer
- 1.5.4 Gastrointestinal Cancer
- 1.5.5 Prostate Cancer
- 1.5.6 Respiratory/Lung Cancer
- 1.5.7 Others
- 1.6 Coronavirus Disease 2019 (Covid-19): Drugs for Oncology Industry Impact
- 1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
- 1.6.2 Covid-19 Impact: Commodity Prices Indices
- 1.6.3 Covid-19 Impact: Global Major Government Policy
- 1.7 Study Objectives
- 1.8 Years Considered
2 Global Growth Trends
- 2.1 Covid-19 Implications on Global Drugs for Oncology Market Perspective (2015-2026)
- 2.2 Covid-19 Implications on Global Drugs for Oncology Growth Trends by Regions
- 2.2.1 Drugs for Oncology Market Size by Regions: 2015 VS 2020 VS 2026
- 2.2.2 Drugs for Oncology Historic Market Share by Regions (2015-2020)
- 2.2.3 Drugs for Oncology Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Challenges
- 2.3.4 Porter’s Five Forces Analysis
- 2.3.5 Drugs for Oncology Market Growth Strategy
- 2.3.6 Primary Interviews with Key Drugs for Oncology Players (Opinion Leaders)
3 Covid-19 Implications on Competition Landscape by Key Players
- 3.1 Global Top Drugs for Oncology Players by Market Size
- 3.1.1 Global Top Drugs for Oncology Players by Revenue (2015-2020)
- 3.1.2 Global Drugs for Oncology Revenue Market Share by Players (2015-2020)
- 3.1.3 Global Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global Drugs for Oncology Market Concentration Ratio
- 3.2.1 Global Drugs for Oncology Market Concentration Ratio (CR5 and HHI)
- 3.2.2 Global Top 10 and Top 5 Companies by Drugs for Oncology Revenue in 2019
- 3.3 Drugs for Oncology Key Players Head office and Area Served
- 3.4 Key Players Drugs for Oncology Product Solution and Service
- 3.5 Date of Enter into Drugs for Oncology Market
- 3.6 Mergers & Acquisitions, Expansion Plans
4 Covid-19 Implications on Market Size by Type (2015-2026)
- 4.1 Global Drugs for Oncology Historic Market Size by Type (2015-2020)
- 4.2 Global Drugs for Oncology Forecasted Market Size by Type (2021-2026)
5 Covid-19 Implications on Market Size by Application (2015-2026)
- 5.1 Global Drugs for Oncology Market Size by Application (2015-2020)
- 5.2 Global Drugs for Oncology Forecasted Market Size by Application (2021-2026)
6 North America Impact of COVID-19
- 6.1 North America Drugs for Oncology Market Size (2015-2020)
- 6.2 Drugs for Oncology Key Players in North America (2019-2020)
- 6.3 North America Drugs for Oncology Market Size by Type (2015-2020)
- 6.4 North America Drugs for Oncology Market Size by Application (2015-2020)
7 Europe Impact of COVID-19
- 7.1 Europe Drugs for Oncology Market Size (2015-2020)
- 7.2 Drugs for Oncology Key Players in Europe (2019-2020)
- 7.3 Europe Drugs for Oncology Market Size by Type (2015-2020)
- 7.4 Europe Drugs for Oncology Market Size by Application (2015-2020)
8 China Impact of COVID-19
- 8.1 China Drugs for Oncology Market Size (2015-2020)
- 8.2 Drugs for Oncology Key Players in China (2019-2020)
- 8.3 China Drugs for Oncology Market Size by Type (2015-2020)
- 8.4 China Drugs for Oncology Market Size by Application (2015-2020)
9 Japan Impact of COVID-19
- 9.1 Japan Drugs for Oncology Market Size (2015-2020)
- 9.2 Drugs for Oncology Key Players in Japan (2019-2020)
- 9.3 Japan Drugs for Oncology Market Size by Type (2015-2020)
- 9.4 Japan Drugs for Oncology Market Size by Application (2015-2020)
10 Southeast Asia Impact of COVID-19
- 10.1 Southeast Asia Drugs for Oncology Market Size (2015-2020)
- 10.2 Drugs for Oncology Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Drugs for Oncology Market Size by Type (2015-2020)
- 10.4 Southeast Asia Drugs for Oncology Market Size by Application (2015-2020)
11 India Impact of COVID-19
- 11.1 India Drugs for Oncology Market Size (2015-2020)
- 11.2 Drugs for Oncology Key Players in India (2019-2020)
- 11.3 India Drugs for Oncology Market Size by Type (2015-2020)
- 11.4 India Drugs for Oncology Market Size by Application (2015-2020)
12 Central & South America Impact of COVID-19
- 12.1 Central & South America Drugs for Oncology Market Size (2015-2020)
- 12.2 Drugs for Oncology Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Drugs for Oncology Market Size by Type (2015-2020)
- 12.4 Central & South America Drugs for Oncology Market Size by Application (2015-2020)
13Key Players Profiles
- 13.1 Roche
- 13.1.1 Roche Company Details
- 13.1.2 Roche Business Overview and Its Total Revenue
- 13.1.3 Roche Drugs for Oncology Introduction
- 13.1.4 Roche Revenue in Drugs for Oncology Business (2015-2020))
- 13.1.5 Roche Recent Development and Reaction to COVID-19
- 13.2 Celgene
- 13.2.1 Celgene Company Details
- 13.2.2 Celgene Business Overview and Its Total Revenue
- 13.2.3 Celgene Drugs for Oncology Introduction
- 13.2.4 Celgene Revenue in Drugs for Oncology Business (2015-2020)
- 13.2.5 Celgene Recent Development and Reaction to COVID-19
- 13.3 Novartis
- 13.3.1 Novartis Company Details
- 13.3.2 Novartis Business Overview and Its Total Revenue
- 13.3.3 Novartis Drugs for Oncology Introduction
- 13.3.4 Novartis Revenue in Drugs for Oncology Business (2015-2020)
- 13.3.5 Novartis Recent Development and Reaction to COVID-19
- 13.4 Bristol-Myers Squibb
- 13.4.1 Bristol-Myers Squibb Company Details
- 13.4.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
- 13.4.3 Bristol-Myers Squibb Drugs for Oncology Introduction
- 13.4.4 Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2015-2020)
- 13.4.5 Bristol-Myers Squibb Recent Development and Reaction to COVID-19
- 13.5 Johnson & Johnson
- 13.5.1 Johnson & Johnson Company Details
- 13.5.2 Johnson & Johnson Business Overview and Its Total Revenue
- 13.5.3 Johnson & Johnson Drugs for Oncology Introduction
- 13.5.4 Johnson & Johnson Revenue in Drugs for Oncology Business (2015-2020)
- 13.5.5 Johnson & Johnson Recent Development and Reaction to COVID-19
- 13.6 Merck & Co.
- 13.6.1 Merck & Co. Company Details
- 13.6.2 Merck & Co. Business Overview and Its Total Revenue
- 13.6.3 Merck & Co. Drugs for Oncology Introduction
- 13.6.4 Merck & Co. Revenue in Drugs for Oncology Business (2015-2020)
- 13.6.5 Merck & Co. Recent Development and Reaction to COVID-19
- 13.7 AstraZeneca
- 13.7.1 AstraZeneca Company Details
- 13.7.2 AstraZeneca Business Overview and Its Total Revenue
- 13.7.3 AstraZeneca Drugs for Oncology Introduction
- 13.7.4 AstraZeneca Revenue in Drugs for Oncology Business (2015-2020)
- 13.7.5 AstraZeneca Recent Development and Reaction to COVID-19
- 13.8 Pfizer
- 13.8.1 Pfizer Company Details
- 13.8.2 Pfizer Business Overview and Its Total Revenue
- 13.8.3 Pfizer Drugs for Oncology Introduction
- 13.8.4 Pfizer Revenue in Drugs for Oncology Business (2015-2020)
- 13.8.5 Pfizer Recent Development and Reaction to COVID-19
- 13.9 Amgen
- 13.9.1 Amgen Company Details
- 13.9.2 Amgen Business Overview and Its Total Revenue
- 13.9.3 Amgen Drugs for Oncology Introduction
- 13.9.4 Amgen Revenue in Drugs for Oncology Business (2015-2020)
- 13.9.5 Amgen Recent Development and Reaction to COVID-19
- 13.10 Eli Lilly
- 13.10.1 Eli Lilly Company Details
- 13.10.2 Eli Lilly Business Overview and Its Total Revenue
- 13.10.3 Eli Lilly Drugs for Oncology Introduction
- 13.10.4 Eli Lilly Revenue in Drugs for Oncology Business (2015-2020)
- 13.10.5 Eli Lilly Recent Development and Reaction to COVID-19
- 13.11 AbbVie
- 10.11.1 AbbVie Company Details
- 10.11.2 AbbVie Business Overview and Its Total Revenue
- 10.11.3 AbbVie Drugs for Oncology Introduction
- 10.11.4 AbbVie Revenue in Drugs for Oncology Business (2015-2020)
- 10.11.5 AbbVie Recent Development and Reaction to COVID-19
- 13.12 Takeda
- 10.12.1 Takeda Company Details
- 10.12.2 Takeda Business Overview and Its Total Revenue
- 10.12.3 Takeda Drugs for Oncology Introduction
- 10.12.4 Takeda Revenue in Drugs for Oncology Business (2015-2020)
- 10.12.5 Takeda Recent Development and Reaction to COVID-19
- 13.13 Astellas
- 10.13.1 Astellas Company Details
- 10.13.2 Astellas Business Overview and Its Total Revenue
- 10.13.3 Astellas Drugs for Oncology Introduction
- 10.13.4 Astellas Revenue in Drugs for Oncology Business (2015-2020)
- 10.13.5 Astellas Recent Development and Reaction to COVID-19
- 13.14 Ipsen
- 10.14.1 Ipsen Company Details
- 10.14.2 Ipsen Business Overview and Its Total Revenue
- 10.14.3 Ipsen Drugs for Oncology Introduction
- 10.14.4 Ipsen Revenue in Drugs for Oncology Business (2015-2020)
- 10.14.5 Ipsen Recent Development and Reaction to COVID-19
- 13.15 Sanofi
- 10.15.1 Sanofi Company Details
- 10.15.2 Sanofi Business Overview and Its Total Revenue
- 10.15.3 Sanofi Drugs for Oncology Introduction
- 10.15.4 Sanofi Revenue in Drugs for Oncology Business (2015-2020)
- 10.15.5 Sanofi Recent Development and Reaction to COVID-19
- 13.16 Bayer
- 10.16.1 Bayer Company Details
- 10.16.2 Bayer Business Overview and Its Total Revenue
- 10.16.3 Bayer Drugs for Oncology Introduction
- 10.16.4 Bayer Revenue in Drugs for Oncology Business (2015-2020)
- 10.16.5 Bayer Recent Development and Reaction to COVID-19
- 13.17 Biogen Idec
- 10.17.1 Biogen Idec Company Details
- 10.17.2 Biogen Idec Business Overview and Its Total Revenue
- 10.17.3 Biogen Idec Drugs for Oncology Introduction
- 10.17.4 Biogen Idec Revenue in Drugs for Oncology Business (2015-2020)
- 10.17.5 Biogen Idec Recent Development and Reaction to COVID-19
- 13.18 Teva
- 10.18.1 Teva Company Details
- 10.18.2 Teva Business Overview and Its Total Revenue
- 10.18.3 Teva Drugs for Oncology Introduction
- 10.18.4 Teva Revenue in Drugs for Oncology Business (2015-2020)
- 10.18.5 Teva Recent Development and Reaction to COVID-19
- 13.19 Otsuka
- 10.19.1 Otsuka Company Details
- 10.19.2 Otsuka Business Overview and Its Total Revenue
- 10.19.3 Otsuka Drugs for Oncology Introduction
- 10.19.4 Otsuka Revenue in Drugs for Oncology Business (2015-2020)
- 10.19.5 Otsuka Recent Development and Reaction to COVID-19
- 13.20 Eisai
- 10.20.1 Eisai Company Details
- 10.20.2 Eisai Business Overview and Its Total Revenue
- 10.20.3 Eisai Drugs for Oncology Introduction
- 10.20.4 Eisai Revenue in Drugs for Oncology Business (2015-2020)
- 10.20.5 Eisai Recent Development and Reaction to COVID-19
- 13.21 Merck KGaA
- 10.21.1 Merck KGaA Company Details
- 10.21.2 Merck KGaA Business Overview and Its Total Revenue
- 10.21.3 Merck KGaA Drugs for Oncology Introduction
- 10.21.4 Merck KGaA Revenue in Drugs for Oncology Business (2015-2020)
- 10.21.5 Merck KGaA Recent Development and Reaction to COVID-19
- 13.22 Gilead Sciences
- 10.22.1 Gilead Sciences Company Details
- 10.22.2 Gilead Sciences Business Overview and Its Total Revenue
- 10.22.3 Gilead Sciences Drugs for Oncology Introduction
- 10.22.4 Gilead Sciences Revenue in Drugs for Oncology Business (2015-2020)
- 10.22.5 Gilead Sciences Recent Development and Reaction to COVID-19
14Analyst's Viewpoints/Conclusions
15Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.2 Data Source
- 15.2 Disclaimer
Summary:
Get latest Market Research Reports on Drugs for Oncology. Industry analysis & Market Report on Drugs for Oncology is a syndicated market report, published as Covid-19 Impact on Global Drugs for Oncology Market Size, Status and Forecast 2020-2026. It is complete Research Study and Industry Analysis of Drugs for Oncology market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
